Wilex and ArcherDx deals see IVD consolidation continue
This article was originally published in Clinica
Executive Summary
Two acquisitions in the in vitro diagnostics field have highlighted the trend for increasing consolidation in the sector, and the medtech industry in general. The first is Nuclea Biotechnologies’ agreed purchase of troubled German biopharma firm Wilex’s US subsidiary, which specializes in companion diagnostics; while the second involves Enzymatics’ buy of next-generation sequencing specialist ArcherDx.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.